<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554590</url>
  </required_header>
  <id_info>
    <org_study_id>DM1cc</org_study_id>
    <nct_id>NCT03554590</nct_id>
  </id_info>
  <brief_title>DM1, Effects of Carbo-Counting on Glycemic Control</brief_title>
  <official_title>Effectiveness of Carbohydrate Counting on Glycaemic Control in T1DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carbohydrate counting is the most effective meal-planning strategy in type 1 diabetes (T1DM)
      to optimize insulin therapy. However, it may lead to weight gain and unhealthy eating habits.
      This study aims to compare glycemic control parameters, anthropometric measurements and
      dietary lifestyle in T1DM patients who practice CHO-counting, after attending a structured
      course to learn how to manage this tecnique, vs a control Group, in a follow up period of 2
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients with type 1 DM will be enrolled in the study. patients in the intervention group
      will attend a 5-lessons training to learn how to manage insulin therapy depending on the
      amount of carbohydrates in their meals, patients in the control group will be follow
      according to the the standard care. after the follow up period glycometabolic, anthropometric
      parameters and dietary lifestyle changes will be compared between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control</measure>
    <time_frame>2 years</time_frame>
    <description>HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anthropometric parameters: BMI</measure>
    <time_frame>2 years</time_frame>
    <description>variations in body mass index (BMI: units kg/m2), weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometric parameters: WAIST AND HIP CIRCUMFERENCE</measure>
    <time_frame>2 years</time_frame>
    <description>variations in waist and hip circumference (units: cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometric parameters: BIOIMPEDENTIOMETRIC PARAMETERS</measure>
    <time_frame>2 years</time_frame>
    <description>fat mass and free fat mass (units: % of total mass)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dietary lifestyle</measure>
    <time_frame>2 years</time_frame>
    <description>variations in intake of simple sugars, animal protein rich foods, saturated fats and cholesterol, UDM: grams/die. All the informations will be collected using 5days food diaries, completed by the patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose variability: mean and standard deviation of self monitoring blood glucose (SMBG)</measure>
    <time_frame>2 YEARS</time_frame>
    <description>mean and standard deviation of self monitoring blood glucose (SMBG), data collected from glucometers, units: mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose variability: incidence of hypoglycaemia</measure>
    <time_frame>2 YEARS</time_frame>
    <description>incidence of hypoglycaemia (SMBG &lt; 70 mg/dl), units: nÂ° episodes/week</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>carbo-counters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>carbohydrate counting</intervention_name>
    <description>patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods</description>
    <arm_group_label>carbo-counters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>insulin therapy according to standard care</intervention_name>
    <description>patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes mellitus

          -  insulin therapy

          -  HbA1c from 5.5 to 10%

        Exclusion Criteria:

          -  pregnancy

          -  celiac disease

          -  hepatic impairment

          -  chronic renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuela Orsi</last_name>
    <role>Principal Investigator</role>
    <affiliation>FOndazione IRCCS Ca' Granda Opedale Maggiore Policlinico Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuela Orsi, MD</last_name>
    <phone>0255034590</phone>
    <email>emanuela_orsi@yahoo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>valeria grancini, MD</last_name>
    <phone>0039 3926233299</phone>
    <email>valeria_grancini@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Grancini, MD</last_name>
      <phone>00393926233299</phone>
      <email>valeria_grancini@hotmail.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</investigator_affiliation>
    <investigator_full_name>Emanuela Orsi</investigator_full_name>
    <investigator_title>Head of DIabetology</investigator_title>
  </responsible_party>
  <keyword>carbohydrate counting</keyword>
  <keyword>insulin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

